Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

DACARBAZINE MEDAC

Package(a):
SINGLE DOSE VIAL (powder for solution for injection/infusion): 1 x 200 mg.
Dosage(a):
Malignant melanoma: As a single agent, 200 to 250 mg/m² body surface area/day as an I.V. injection for 5 days every 3 weeks. Alternatively, can be administered as a short-term infusion (over 15-30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as I.V. infusion. 
Hodgkin's disease: 375 mg/m² body surface area I.V. every 15 days in combination with doxorubicin, bleomycin and vinblastine. See prescribing information for more details.
Prescribing Restrictions:  

Package(b):
SINGLE DOSE VIALS (powder for solution for injection/infusion): 10 x 200 mg.
Dosage(b):
Malignant melanoma: As a single agent, 200 to 250 mg/m² body surface area/day as an I.V. injection for 5 days every 3 weeks. Alternatively, can be administered as a short-term infusion (over 15-30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as I.V. infusion. 
Hodgkin's disease: 375 mg/m² body surface area I.V. every 15 days in combination with doxorubicin, bleomycin and vinblastine. See prescribing information for more details.
Prescribing Restrictions:  None

Package(c):
SINGLE DOSE VIAL (powder for solution for infusion): 1 x 500 mg.
Dosage(c):
Malignant melanoma: As a single agent, 200 to 250 mg/m² body surface area/day as an I.V. injection for 5 days every 3 weeks. Alternatively, can be administered as a short-term infusion (over 15-30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as I.V. infusion. 
Hodgkin's disease: 375 mg/m² body surface area I.V. every 15 days in combination with doxorubicin, bleomycin and vinblastine. See prescribing information for more details.
Prescribing Restrictions:  None

Package(d):
SINGLE DOSE VIALS (powder for solution for infusion): 10 x 500 mg.
Dosage(d):
Malignant melanoma: As a single agent, 200 to 250 mg/m² body surface area/day as an I.V. injection for 5 days every 3 weeks. Alternatively, can be administered as a short-term infusion (over 15-30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as I.V. infusion. 
Hodgkin's disease: 375 mg/m² body surface area I.V. every 15 days in combination with doxorubicin, bleomycin and vinblastine. See prescribing information for more details.
Prescribing Restrictions:  None

Package(e):
SINGLE DOSE VIAL (powder for solution for infusion): 1 x 1,000 mg.
Dosage(e):
Malignant melanoma: As a single agent, 200 to 250 mg/m² body surface area/day as an I.V. injection for 5 days every 3 weeks. Alternatively, can be administered as a short-term infusion (over 15-30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as I.V. infusion. 
Hodgkin's disease: 375 mg/m² body surface area I.V. every 15 days in combination with doxorubicin, bleomycin and vinblastine. See prescribing information for more details.
Prescribing Restrictions:  None

Package(f):
SINGLE DOSE VIALS (powder for solution for infusion): 10 x 1,000 mg.
Dosage(f):
Malignant melanoma: As a single agent, 200 to 250 mg/m² body surface area/day as an I.V. injection for 5 days every 3 weeks. Alternatively, can be administered as a short-term infusion (over 15-30 minutes). It is also possible to give 850 mg/m² body surface area on day 1 and then once every 3 weeks as I.V. infusion. 
Hodgkin's disease: 375 mg/m² body surface area I.V. every 15 days in combination with doxorubicin, bleomycin and vinblastine. See prescribing information for more details.
Prescribing Restrictions:  None


Indications:
Treatment of metastatic malignant melanoma. As a second line treatment: Part of a combination chemotherapy in advanced Hodgkin's disease.
Contra-Indications:
History of hypersensitivity reactions to dacarbazine, pregnancy and lactation, leucopenia and/or thrombocytopenia, severe liver or kidney diseases.
Special Precautions:
See prescribing information for full details.
Side Effects:
See prescribing information for full details.
Drug Interactions:
See prescribing information for full details.